ECORHIGH SIGNALFINANCIAL10-K

ECOR's stockholders' equity collapsed from $7.5M to negative $1.7M while liabilities surged 58%, indicating severe financial distress despite revenue growth.

The company has moved into negative equity territory, a critical warning sign that total liabilities now exceed total assets by $1.7M. This dramatic deterioration in the balance sheet structure suggests potential solvency concerns and may trigger debt covenant issues or financing difficulties, despite operational improvements in revenue and gross profit.

Comparing 2026-03-19 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

While ECOR showed operational progress with revenue growing 27% to $32M and gross profit increasing 30% to $27.8M, the financial picture is deeply concerning as stockholders' equity turned negative and total liabilities jumped 58% to $20.4M. The company did improve its cash position by doubling to $7M and significantly reduced R&D spending by 56%, but these positive moves were overshadowed by the balance sheet deterioration. The combination of negative equity, rising liabilities, and increased SG&A expenses signals a company struggling with financial stability despite top-line growth.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-122.7%
$7.5M→-$1.7M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Cash & Equivalents
Balance Sheet
+103.9%
$3.5M→$7.0M

Cash position surged 103.9% — strong cash generation or capital raise providing significant financial cushion.

Capital Expenditure
Cash Flow
-68%
$206K→$66K

Capex reduced 68% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Liabilities
Balance Sheet
+57.6%
$12.9M→$20.4M

Liabilities grew 57.6% — significant increase in debt or obligations, assess impact on financial flexibility.

R&D Expense
P&L
-55.6%
$5.3M→$2.4M

R&D spending cut 55.6% — could signal cost discipline or concerning reduction in innovation investment.

Gross Profit
P&L
+29.9%
$21.4M→$27.8M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Revenue
P&L
+27.2%
$25.2M→$32.0M

Revenue growing 27.2% — solid top-line momentum, watch margins for quality of growth.

Accounts Receivable
Balance Sheet
-24.9%
$1.4M→$1.0M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Current Liabilities
Balance Sheet
+24%
$9.2M→$11.3M

Current liabilities rose 24% — increased short-term obligations, watch current ratio.

SG&A Expense
P&L
+22.5%
$31.2M→$38.2M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-12
ADDED
(Exact name of Registrant as specified in its Charter) Delaware 20-3454976 (State or other jurisdiction of incorporation or organization) (I.R.S.
See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
References to electroCore In this Annual Report, unless otherwise stated or the context otherwise indicates, references to ECOR, electroCore, the Company, we, us, our and similar references refer to electroCore, Inc., a Delaware corporation and its wholly owned subsidiaries, including NeuroMetrix, Inc., a Delaware corporation ( NeuroMetrix or NURO ).
We are subject to risks associated with the commercialization of our product offering through ecommerce marketplaces.
We recently launched our next generation prescription gammaCore device under the brand gammaCore Emerald, and there can be no assurance that the new device will be well received or adopted, which may impact our financial results.
+7 more — sign up free →
REMOVED
(Exact n ame of Registrant as specified in its Charter) Delaware 20-3454976 (State or other jurisdiction of incorporation or organization) (I.R.S.
See the definitions of large accelerated filer, accelerated file r, smaller reporting company, and emerging growth company in Rule 12 b- 2 of the Exchange Act.
References to electroCore In this Annual Report, unless otherwise stated or the context otherwise indicates, references to ECOR, electroCore, the Company, we, us, our and similar references refer to electroCore, Inc., a Delaware corporation.
We have a limited history commercializing our nVNS platform technology, including cash pay initiates such as our gConcierge and gCDirect programs, as well as through direct-to-consumer channels, and commercial success is uncertain.
We recently launched our next generation app-enabled consumer wellness product under the brand Truvaga, and there can be no assurance that the new product will be well received or adopted, which may impact our financial results.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →